Table 2 Efficacy results in patients without prior antimicrobial failure in the mCRE-MITT population [17]
From: Clinical Outcomes of Patient Subgroups in the TANGO II Study
Efficacy endpoints (mCRE-MITT) | Meropenem–vaborbactam (n = 23) | Best available therapy (n = 15) | Absolute difference (95% CI) |
---|---|---|---|
Clinical cure at TOC | 16 (69.6) | 4 (26.7) | + 42.9 (+ 13.7 to + 72.1) |
Clinical cure at EOT | 19 (82.6) | 5 (33.3) | + 49.3 (+ 20.8 to + 77.7) |
Microbiologic curea at EOT | 19 (82.6) | 6 (40.0) | + 42.6 (+ 13.4 to + 71.8) |
Microbiologic curea at TOC | 16 (69.6) | 5 (33.3) | + 36.2 (+ 5.9 to + 66.6) |
Day-28 mortality | 1 (4.3) | 5 (33.3) | − 29.0 (− 54.3 to − 3.7) |